NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials
April 22, 2016 09:30 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, April 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today...
NeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting
April 05, 2016 07:00 ET
|
NeuroDerm Ltd.
- An Encore Presentation on ND0612 Will be Given at the Invited Science: Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance...
NeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update
March 31, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, March 31, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today...
NeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016
March 22, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, March 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today...
NeuroDerm to Present at Upcoming Investor Conferences
March 02, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, March 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 14, 2016
January 04, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Jan. 04, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease
December 30, 2015 07:08 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 30, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Added to the Nasdaq Biotechnology Index
December 18, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 18, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Upcoming Investor Conferences
November 12, 2015 16:05 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Third Quarter 2015 Financial Results
November 11, 2015 07:02 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...